Sigal Fattal
Financieel Directeur/CFO bij CHEMOMAB THERAPEUTICS LTD.
Vermogen: 494 $ op 30-04-2024
Actieve functies van Sigal Fattal
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
CHEMOMAB THERAPEUTICS LTD. | Financieel Directeur/CFO | 01-06-2023 | - |
Corporate Officer/Principal | 08-11-2021 | 01-06-2023 |
Loopbaan van Sigal Fattal
Eerdere bekende functies van Sigal Fattal
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BiomX Ltd.
BiomX Ltd. Pharmaceuticals: MajorHealth Technology BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel. | Financieel Directeur/CFO | 01-03-2017 | 01-12-2019 |
EVOGENE LTD. | Financieel Directeur/CFO | 01-06-2012 | 01-01-2016 |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Financieel Directeur/CFO | - | - |
Opleiding van Sigal Fattal
Tel-Aviv University | Masters Business Admin |
Statistieken
Internationaal
Israël | 6 |
Operationeel
Director of Finance/CFO | 4 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 5 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
EVOGENE LTD. | Health Technology |
CHEMOMAB THERAPEUTICS LTD. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Health Technology |
BiomX Ltd.
BiomX Ltd. Pharmaceuticals: MajorHealth Technology BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel. | Health Technology |
- Beurs
- Insiders
- Sigal Fattal
- Ervaring